Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Análogo de la melatonina para el tratamiento del cáncer

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20150824002
Publicado:
01/09/2015
Caducidad:
31/08/2016
Resumen:
Un grupo español de investigación médica ha desarrollado un análogo de la melatonina para el tratamiento del cáncer. El grupo ha descubierto que un análogo específico de la melatonina, la agomelatina, inhibe el crecimiento de líneas celulares del cáncer de colon in vitro e in vivo, y sugiere el papel oncostático/citotóxico de este compuesto. La composición puede administrarse mediante cualquier método adecuado, combinarse con otros componentes y utilizarse como suplemento dietético. El grupo de investigación busca socios de los sectores público y privado para establecer acuerdos de licencia o lanzar el producto al mercado.

Details

Tittle:
Melatonin analogous for cancer treatment
Summary:
A Spanish medial research group has developed a Melatonin analogue to treat cancer. The composition can be administered by any suitable method, can be combined with other components and can be used as a dietary supplement. This research group is looking to establish a license agreement or an agreement for public-private partnership to bring the product to the market.
Description:
Melatonin affects cell proliferation in a variety of tumor cell lines, both in physiological and pharmacological concentrations.

A Spanish medical research group working in a mayor hospital has demonstrated that a specific melatonin analogue, called Agomelatine, inhibits the growth of cell lines of colon cancer in vitro and in vivo, suggesting the oncostatic / cytotoxic role of this compound.The composition can be administered by any suitable method, can be combined with other components and can be used as a dietary supplement.

This research group is looking to establish a license agreement or an agreement for public-private partnership to bring the product to the market.
Advantages and Innovations:
- This pharmaceutical composition may be administered by any suitable method, such as intravenous infusion and oral, topical or parenteral routes.

- The composition can be combined with other components and can be used as a nutritional or dietary supplement.
Stage of Development:
Field tested/evaluated
IPs:
Patent(s) applied for but not yet granted

Partner sought

Type and Role of Partner Sought:
This research group is looking to establish a license
agreement or agreement for public-private
partnership for further development of technology.

- Type of partner sought: Biotech/Pharma or Food Companies

- Specific area of activity of the partner: Oncology or Nutraceutical (in case of Food Companies)

- Task to be performed: Further development to clinical stage and bringing the product to the market.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001003 Citología, cancerología, oncología